Cargando…
Assessing Osteolytic Lesion Size on Sequential CT Scans Is a Reliable Study Endpoint for Bone Remineralization in Newly Diagnosed Multiple Myeloma
SIMPLE SUMMARY: While MRI is primarily used for vitality analysis in multiple myeloma, the detection of osteolytic manifestations in the mineralized bone is performed on CT scans. For this study based on a homogenous sample of 20 patients with newly diagnosed multiple myeloma, we hypothesized that s...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417114/ https://www.ncbi.nlm.nih.gov/pubmed/37568823 http://dx.doi.org/10.3390/cancers15154008 |
_version_ | 1785087944997994496 |
---|---|
author | Grunz, Jan-Peter Kunz, Andreas Steven Baumann, Freerk T. Hasenclever, Dirk Sieren, Malte Maria Heldmann, Stefan Bley, Thorsten Alexander Einsele, Hermann Knop, Stefan Jundt, Franziska |
author_facet | Grunz, Jan-Peter Kunz, Andreas Steven Baumann, Freerk T. Hasenclever, Dirk Sieren, Malte Maria Heldmann, Stefan Bley, Thorsten Alexander Einsele, Hermann Knop, Stefan Jundt, Franziska |
author_sort | Grunz, Jan-Peter |
collection | PubMed |
description | SIMPLE SUMMARY: While MRI is primarily used for vitality analysis in multiple myeloma, the detection of osteolytic manifestations in the mineralized bone is performed on CT scans. For this study based on a homogenous sample of 20 patients with newly diagnosed multiple myeloma, we hypothesized that sequential CT studies can be used to validate remineralization quantitatively and qualitatively as a measure of treatment response. After six cycles of standardized induction therapy with the anti-SLAMF7 antibody elotuzumab in combination with carfilzomib, lenalidomide, and dexamethasone (E-KRd), we were able to record a substantial lesion size decrease associated with the formation of trabecular sclerosis in the majority of responding manifestations. ABSTRACT: Multiple myeloma (MM) frequently induces persisting osteolytic manifestations despite hematologic treatment response. This study aimed to establish a biometrically valid study endpoint for bone remineralization through quantitative and qualitative analyses in sequential CT scans. Twenty patients (seven women, 58 ± 8 years) with newly diagnosed MM received standardized induction therapy comprising the anti-SLAMF7 antibody elotuzumab, carfilzomib, lenalidomide, and dexamethasone (E-KRd). All patients underwent whole-body low-dose CT scans before and after six cycles of E-KRd. Two radiologists independently recorded osteolytic lesion sizes, as well as the presence of cortical destruction, pathologic fractures, rim and trabecular sclerosis. Bland–Altman analyses and Krippendorff’s α were employed to assess inter-reader reliability, which was high for lesion size measurement (standard error 1.2 mm) and all qualitative criteria assessed (α ≥ 0.74). After six cycles of E-KRd induction, osteolytic lesion size decreased by 22% (p < 0.001). While lesion size response did not correlate with the initial lesion size at baseline imaging (Pearson’s r = 0.144), logistic regression analysis revealed that the majority of responding osteolyses exhibited trabecular sclerosis (p < 0.001). The sum of osteolytic lesion sizes on sequential CT scans defines a reliable study endpoint to characterize bone remineralization. Patient level response is strongly associated with the presence of trabecular sclerosis. |
format | Online Article Text |
id | pubmed-10417114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104171142023-08-12 Assessing Osteolytic Lesion Size on Sequential CT Scans Is a Reliable Study Endpoint for Bone Remineralization in Newly Diagnosed Multiple Myeloma Grunz, Jan-Peter Kunz, Andreas Steven Baumann, Freerk T. Hasenclever, Dirk Sieren, Malte Maria Heldmann, Stefan Bley, Thorsten Alexander Einsele, Hermann Knop, Stefan Jundt, Franziska Cancers (Basel) Article SIMPLE SUMMARY: While MRI is primarily used for vitality analysis in multiple myeloma, the detection of osteolytic manifestations in the mineralized bone is performed on CT scans. For this study based on a homogenous sample of 20 patients with newly diagnosed multiple myeloma, we hypothesized that sequential CT studies can be used to validate remineralization quantitatively and qualitatively as a measure of treatment response. After six cycles of standardized induction therapy with the anti-SLAMF7 antibody elotuzumab in combination with carfilzomib, lenalidomide, and dexamethasone (E-KRd), we were able to record a substantial lesion size decrease associated with the formation of trabecular sclerosis in the majority of responding manifestations. ABSTRACT: Multiple myeloma (MM) frequently induces persisting osteolytic manifestations despite hematologic treatment response. This study aimed to establish a biometrically valid study endpoint for bone remineralization through quantitative and qualitative analyses in sequential CT scans. Twenty patients (seven women, 58 ± 8 years) with newly diagnosed MM received standardized induction therapy comprising the anti-SLAMF7 antibody elotuzumab, carfilzomib, lenalidomide, and dexamethasone (E-KRd). All patients underwent whole-body low-dose CT scans before and after six cycles of E-KRd. Two radiologists independently recorded osteolytic lesion sizes, as well as the presence of cortical destruction, pathologic fractures, rim and trabecular sclerosis. Bland–Altman analyses and Krippendorff’s α were employed to assess inter-reader reliability, which was high for lesion size measurement (standard error 1.2 mm) and all qualitative criteria assessed (α ≥ 0.74). After six cycles of E-KRd induction, osteolytic lesion size decreased by 22% (p < 0.001). While lesion size response did not correlate with the initial lesion size at baseline imaging (Pearson’s r = 0.144), logistic regression analysis revealed that the majority of responding osteolyses exhibited trabecular sclerosis (p < 0.001). The sum of osteolytic lesion sizes on sequential CT scans defines a reliable study endpoint to characterize bone remineralization. Patient level response is strongly associated with the presence of trabecular sclerosis. MDPI 2023-08-07 /pmc/articles/PMC10417114/ /pubmed/37568823 http://dx.doi.org/10.3390/cancers15154008 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Grunz, Jan-Peter Kunz, Andreas Steven Baumann, Freerk T. Hasenclever, Dirk Sieren, Malte Maria Heldmann, Stefan Bley, Thorsten Alexander Einsele, Hermann Knop, Stefan Jundt, Franziska Assessing Osteolytic Lesion Size on Sequential CT Scans Is a Reliable Study Endpoint for Bone Remineralization in Newly Diagnosed Multiple Myeloma |
title | Assessing Osteolytic Lesion Size on Sequential CT Scans Is a Reliable Study Endpoint for Bone Remineralization in Newly Diagnosed Multiple Myeloma |
title_full | Assessing Osteolytic Lesion Size on Sequential CT Scans Is a Reliable Study Endpoint for Bone Remineralization in Newly Diagnosed Multiple Myeloma |
title_fullStr | Assessing Osteolytic Lesion Size on Sequential CT Scans Is a Reliable Study Endpoint for Bone Remineralization in Newly Diagnosed Multiple Myeloma |
title_full_unstemmed | Assessing Osteolytic Lesion Size on Sequential CT Scans Is a Reliable Study Endpoint for Bone Remineralization in Newly Diagnosed Multiple Myeloma |
title_short | Assessing Osteolytic Lesion Size on Sequential CT Scans Is a Reliable Study Endpoint for Bone Remineralization in Newly Diagnosed Multiple Myeloma |
title_sort | assessing osteolytic lesion size on sequential ct scans is a reliable study endpoint for bone remineralization in newly diagnosed multiple myeloma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417114/ https://www.ncbi.nlm.nih.gov/pubmed/37568823 http://dx.doi.org/10.3390/cancers15154008 |
work_keys_str_mv | AT grunzjanpeter assessingosteolyticlesionsizeonsequentialctscansisareliablestudyendpointforboneremineralizationinnewlydiagnosedmultiplemyeloma AT kunzandreassteven assessingosteolyticlesionsizeonsequentialctscansisareliablestudyendpointforboneremineralizationinnewlydiagnosedmultiplemyeloma AT baumannfreerkt assessingosteolyticlesionsizeonsequentialctscansisareliablestudyendpointforboneremineralizationinnewlydiagnosedmultiplemyeloma AT hasencleverdirk assessingosteolyticlesionsizeonsequentialctscansisareliablestudyendpointforboneremineralizationinnewlydiagnosedmultiplemyeloma AT sierenmaltemaria assessingosteolyticlesionsizeonsequentialctscansisareliablestudyendpointforboneremineralizationinnewlydiagnosedmultiplemyeloma AT heldmannstefan assessingosteolyticlesionsizeonsequentialctscansisareliablestudyendpointforboneremineralizationinnewlydiagnosedmultiplemyeloma AT bleythorstenalexander assessingosteolyticlesionsizeonsequentialctscansisareliablestudyendpointforboneremineralizationinnewlydiagnosedmultiplemyeloma AT einselehermann assessingosteolyticlesionsizeonsequentialctscansisareliablestudyendpointforboneremineralizationinnewlydiagnosedmultiplemyeloma AT knopstefan assessingosteolyticlesionsizeonsequentialctscansisareliablestudyendpointforboneremineralizationinnewlydiagnosedmultiplemyeloma AT jundtfranziska assessingosteolyticlesionsizeonsequentialctscansisareliablestudyendpointforboneremineralizationinnewlydiagnosedmultiplemyeloma |